Recent Updates
Recently added Catalysts
VTRS

Viatris Publishes Sustainability Report Highlighting 2021 Progress, Achievements and Goals Viatris Inc. (NASDAQ: VTRS), a global pharmaceutical company, today published its 2021 Sustainability Report, outlining the company's 2021...

Key Takeaway: PITTSBURGH , May 16, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ), a global pharmaceutical company, today published its 2021 Sustainability Report , outlining the company's 2021 achievements and progress across key areas including Access and Global Health, Employees, Environ

Full Press Release Details

PITTSBURGH , May 16, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ), a global pharmaceutical company, today published its 2021 Sustainability Report , outlining the company's 2021 achievements and progress across key areas including Access and Global Health, Employees, Environmental Stewardship and Community Engagement and including details on Viatris' continued efforts to support employees and their families while maintaining a stable supply of medicines during the ongoing COVID-19 pandemic.
As part of the report, the company committed to initial company-wide and multi-year goals in three key areas – access, the environment and diversity, equity and inclusion (DE&I). These include providing antiretroviral (ARV) therapy equivalent to a total of 30 million patients, including more than two million children living with HIV/ AIDS, between 2022 and the end of 2025; impacting 100 million patients via healthcare professional education and outreach regarding prevention, diagnosis and treatment options for cardiovascular disease, diabetes, cancer and other important chronic conditions to improve outcomes through the NCD Academy by the end of 2025. Viatris has committed to reducing absolute Scope 1 and 2 greenhouse gas (GHG) emissions 42% by 2030 and reducing Scope 3 GHG emissions covering purchase goods and services, capital goods, fuel and energy related alternatives and upstream transportation and distribution 25% by 2030. The company has also set goals to enhance DE&I in support of attracting, developing and retaining diverse talent and building a more inclusive environment.
"At Viatris, we believe companies can be a force for good. Our colleagues around the world strive to make a positive difference and during our first full year as Viatris, they truly exemplified the power that lies in collaboration, focus and resilience," said Michael Goettler , CEO for Viatris. "We are proud of the strong foundation we have built, the progress we have made and our commitment to acting responsibly as we support providing sustainable access to medicine for patients around the world, regardless of geography or circumstance, while building a simpler, stronger and more focused company."
Here are some of Viatris' key initiatives, progress and accomplishments in 2021, in collaboration with our partners:
"At Viatris, our commitment to access to medicine and supporting resilient healthcare systems by advancing sustainable and responsible operations truly is a collective mission, realized through the dedication of colleagues across the organization," said Lara Ramsburg , Head of Corporate Affairs of Viatris.
Viatris is dedicated to transparent annual reporting on environmental, social and governance matters, continuously working to further enhance its disclosures.
To learn more about how the company partners with stakeholders throughout the globe to address some of the world's most pressing health, environmental and social issues, click here .
About Viatris Viatris Inc. (NASDAQ: VTRS ) is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a portfolio of biosimilars and a variety of over-the-counter consumer products. With approximately 37,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in Pittsburgh , Shanghai and Hyderabad, India . Learn more at viatris.com and investor.viatris.com , and connect with us on Twitter at @ViatrisInc , LinkedIn and YouTube .
SOURCE Viatris Inc.

21 %

About Viatris Inc.

Ticker Symbol: VTRS
Exchange: NASDAQ
Mission: Empower people worldwide to live healthier at every stage of life
Patient Reach: ~1 billion patients annually
Global Centers: Pittsburgh, Shanghai, Hyderabad
Last updated: May 16, 2022